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perform the validation (Table 1). Our validation resulted in 
an AUC of 0.62. The AUC increased to 0.76 after we removed 
all duplicate patients due to multiple false-positive tumor 
length 'hits' per patient during automated free text 
search.
 
 
Conclusions: We describe a method to extract data from 
multiple sources, and to apply a prediction model on routine 
clinical patient data. Although the free text extraction was 
not perfect and the number of patients in our validation was 
low (N=38), we have successfully shown a method for 
automatically (nightly) applying prediction models in clinical 
practice, and thus enabling use of prediction results for 
treatment decisions. Unfortunately, there is still a need to 
enhance data collection at the source. For example, the 
availability of pCR was our most limiting factor (only 4% of 
patients). Furthermore, the extraction of tumor length from 
free text reports remains necessary until available in a 
structured format. 
Based on this method, future work consists of adding more 
data sources and routine clinical validation of prediction 
models.  
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Purpose/Objective: A re-organisation of surgery of rectal 
cancer among reference hospitals was implemented in 2011 
based on the results of a clinical audit. The aim of this study 
was to assess the impact of centralization of rectal cancer 
surgery on radiotherapy patterns of care and its impact on 
clinical outcomes. 
Materials and Methods: Quality of rectal cancer care was 
assessed by means of a clinical audit (retrospective cohort 
study) of all patients receiving treatment for rectal cancer 
with a radical intent in public hospitals in Catalonia in two-
time periods (2005/7 and 2011/12). Radiotherapy patterns of 
care as well as clinical outcomes, comparing both periods, 
were analysed in order to measure the impact of 
centralization. Clinical practice was compared with evidence-
based clinical guidelines.  
Results: From 2005/7 to 2011/12 the number of hospitals 
performing rectal cancer surgery decreased from 51 to 29. 
The study covered 2553 patients with TNM stage-II or III 
primary rectal cancer. From 2005/7 to 2011/12 the number 
of patients receiving radiotherapy for their rectal cancer, 
either pre o postoperatively, has increased from 72.2 to 
76.2% (p=0.025). Delivering pre-operative radiotherapy ± 
chemotherapy (RT/ChT) increased from 57.3 to 66.2% 
(p<0.001). Short course radiotherapy increased from 2% to 
7%. 
When comparing patient characteristics broken down by 
neo(adjuvant) treatment, patients with pre-operative 
RT/ChT are marked by: a younger age; a lower surgical risk 
and a tumour site more frequently located in the distal 
rectum, and this in both periods. 
The crude local recurrence rate at 1 year of follow-up was 
3.1%.  
The results of the univariate COX regression analyse showed a 
local-recurrence rate hazard ratio of 1.9 for the group of 
patients that did not receive any radiotherapy versus the 
group that received preoperative radiotherapy (p=0.019). In 
the multivariate COX regression analysis, TNM stage, type of 
neo(adjuvant) treatment and type of surgical intervention 
were independent predictors of risk of local recurrence at 1 
year of follow-up. 
Further follow-up is ongoing. 
Conclusions: Centralising surgery into high volume providers 
could be associated with improved adherence to radiotherapy 
recommendations, possibly as a result of more structured 
multidisciplinary decisions.  
Health policy approach combining assessment from the 
clinical audit with reorganisation of the delivery of complex 
treatments has been associated with better outcomes. A 
model of care based on the centralisation of high-complexity 
cancer treatments should be supported by managed regional 
networks and improved referral of patients.  
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Purpose/Objective: Intensity modulated radiotherapy 
(IMRT), including volumetric arc therapy (VMAT) and helical 
IMRT (HT) techniques, has been only recently introduced in 
the treatment of anal canal cancer patients. We 
retrospectively assessed efficacy and safety of IMRT, VMAT, 
HT and daily image-guided RT (IGRT) for anal canal cancer. 
Materials and Methods: Data of patients with a diagnosis of 
anal canal squamous-cell carcinoma treated with curative 
intent in two academic radiation oncology departments were 
analyzed. Local control (LC) and grade 3 or more toxicity rate 
(CTC-AE v.4.0) were the primary endpoints. Overall (OS), 
disease-free (DFS), and colostomy-free survival (CFS) are also 
reported. Anal canal, mesorectal, pelvic, and inguinal nodes 
received a total dose of 36 Gy (1.8 Gy/fr) using IMRT or VMAT 
or HT (depending on the treating center). A sequential boost 
to the anal canal and positive nodes (total dose: 59.4-60 
Gy,1.8-2 Gy/fr) was delivered with IMRT, VMAT, HT or 3D-
conformal RT (CRT). Planning target volume was obtained 
adding 5-mm margin to the clinical target volume. 
Results: Between 03.2006 and 05.2014, a total of 137 
patients was treated; 15, 62, 31 and 28 patients presented 
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stage I, II, IIIA, and IIIB, respectively. Median age was 61.7 
years (range: 35-87). After a median planned gap of 2 weeks 
(range, 0-4; no gap in 25 patients since 2011), a boost dose 
was delivered with either IMRT (n = 16, until 2011), VMAT (n 
= 16), HT (n = 37) or 3D-CRT (n = 68). Concomitant CTX was 
delivered in 127 patients, maily using a mitomycine-
capecitabine combination (n = 117). Median follow-up was 42 
months (range: 2-97). Four-year LC, OS, DFS, and CFS rates 
were 80%, 84%, 78% and 90%, respectively. Time to 
progression was 4 months (range: 0-41). A total of 24 patients 
presented a recurrence (local only in 14, locoregional in 1, 
locoregional and distant in 1, local and distant in 3, regional 
only in 2, and distant only in 3 patients). Twelve patients 
underwent a colostomy because of local recurrence (n = 12) 
or pretreatment dysfunction (n = 2). Grade 3 acute toxicity 
was observed in 33 patients (2.4%); i.e. erythema (26/33) or 
diarrhoea (9/33). No late G3 cutaneous toxicity was 
recorded. At the time of analysis, 127 patients presented 
more than 6 months of followup and were considered 
evaluable for late toxicity: 5 of 127 patients present a late 
G3 gastrointestinal toxicity (anal incontinence). No G4 acute 
or late toxicity was recorded. No significant difference was 
observed in terms of local control or acute G3 toxicity 
between MRT techniques and 3D-CRT boost techniques. 
Conclusions: A total dose of 59.4 Gy to the anal canal and 
involved nodes, including 36 Gy to the uninvolved nodes, is 
effective and safe when delivered using modern IMRT 
techniques and daily IGRT. For these reasons, VMAT or HT 
and concurrent CTX are the standard of care in our 
institutions. 
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Purpose/Objective: To evaluate the efficacy of proton beam 
therapy (PBT) for hepatocellular carcinoma with extensive 
tumor thrombosis in the main trunk or major branches of the 
portal vein. 
Materials and Methods: Eighty patients with hepatocellular 
carcinoma were treated by PBT. There were 65 men and 15 
women, and the median age was 65 years old (range: 25 – 
88). The CTV ranged from 15.2 cm3 to 1687 cm3 (median: 
238.9 cm3). The clinical stages were 3B, 3C, 4A, and 4B in 65, 
1, 5, and 9 patients, respectively. Thirty-two patients had 
primary tumors, and 48 had recurrent tumors. The delivered 
total dose ranged from 70 to 80.47 Gy10 (median: 80.47Gy10) 
in terms of equivalent dose in 2Gy fractions. 
Results: Seventy-seven patients (96.3%) completed the 
planned treatment. Median survival rate for all the patients 
was 12 months. MST for the patients treated with PTV that 
encompassed all the detectable lesions was 26.9 months, and 
MST for the patients who had viable tumor outside of their 
PTV was 6.3 months. Local recurrence after PBT was 
observed in 3 patients. Forty-five patients died of tumor 
progression, and 28 of them had recurrence out of the PTV. 
Multivariate analysis revealed existence of viable tumor 
outside of the PTV, clinical stage, and value of des-gamma-
carboxy prothrombin as significant factors affecting the OS. 
Conclusions: PBT was effective for patients with extensive 
portal tumor thrombus, if the PTV encompassed all the 
detectable lesions.  
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Purpose/Objective: Some studies already showed that acute 
toxicity during chemo +/- radiotherapy (CT +/- RT) was 
correlated to the clinical response of the tumor. In this 
retrospective study, we report our analysis of acute toxicity 
of rectal cancer cancer patients treated with an homogenous 
schedule of CT +/- RT. 
Materials and Methods: Between 01/2010 and 08/2014, 83 
locally advanced rectal cancer patients consecutively treated 
in our institution were analyzed. All these patients received 
long-course neoadjuvant chemoradiotherapy (45 Gy on pelvic 
nodes and mesorectum and 50 Gy on gross tumor volume and 
corresponding mesorectum, delivered with a simultaneous 
integrated boost). All patients were treated with helical 
Tomotherapy (HT) and daily image guided radiotherapy, and 
all of them underwent radical surgery. Concomitant 
chemotherapy with oral capecitabine was delivered in all the 
patients. Primary endpoint of this study was to report the 
rate of acute toxicity (G2 or more) of this therapeutic 
approach and to correlate acute toxicity to the Mandard 
tumor regression rate (TRG). Toxicity were retrospectively 
scored using CTC-AE score (v. 4.0). The considered acute 
toxicity were: skin toxicity, diarrhoea, blood loss, cystitis, 
anorectal pain. We performed logistic regression analyses, 
and we correlated the TRG with the presence of acute 
toxicity (any grade), the presence of any acute toxicity grade 
> 2, and with a 'sum of toxicity' (ST) of each toxicity grades 
(i.e: this ST in a patient presenting a G2 bladder toxicity , a 
G1 pain and a G3 diarrhoea was 6, 2+1+3). 
Results: Globally, 22/83 patients presented an acute > G2 
toxicity (26.5%), with only one patients presenting a G3 acute 
skin toxicity. Data about TRG were available for 69 patients. 
Logistic regression showed that better TRG have been found 
in patients presenting higher TS, both when TRG was 
considered as an ordinal (p=0.028) or as a continuous variable 
(p=0.03). 
